Estamos no ar no ! Saiba mais

AVDL

Avadel Pharmaceuticals

AVDL

Valor de mercado US$ 2,12 bi

Deslistada

AVDL foi retirado da bolsa em 11 de fevereiro de 2026.

Voltar ao ranking

Sobre: Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

Funcionários: 188

Saúde Fabricantes de medicamentos — especializados e genéricos

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 0%

Neutro 0%

Negativo 0%

Form 8.3 - Avadel Pharmaceuticals plc

FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORM A TION Name of person dealing (Note 1) State Street Global Advisors & Affiliates Company dealt in Avadel Pharmaceuticals plc Class of relevant security to which the dealings being disclosed relate (Note 2) $0.01 ordinary shares Date of dealing 11th February 2026 2.

Form 8.3 - Avadel Pharmaceuticals plc

Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) (“Alkermes”) and Avadel Pharmaceuticals plc (Nasdaq: AVDL) (“Avadel”) today announced Alkermes' completion of its acquisition of Avadel, a commercial-stage biopharmaceutical company. The acquisition adds Avadel's FDA-approved product, LUMRYZ®, to Alkermes' commercial portfolio, and provides Alkermes with a commercial organization experienced in this disease state. This strategic move accelerates Alkermes' entry into the sleep medicine market.

Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market

Form 8.3 -Avadel Pharmaceuticals plc

FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORM A TION Name of person dealing (Note 1) State Street Global Advisors & Affiliates Company dealt in Avadel Pharmaceuticals plc Class of relevant security to which the dealings being disclosed relate (Note 2) $0.01 ordinary shares Date of dealing 10th February 2026 2.

Form 8.3 -Avadel Pharmaceuticals plc

Avadel Pharmaceuticals Announces Outcome of the Court Sanction Hearing

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

Avadel Pharmaceuticals Announces Outcome of the Court Sanction Hearing

Form 8.3 -Avadel Pharmaceuticals plc

FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORM A TION Name of person dealing (Note 1) State Street Global Advisors & Affiliates Company dealt in Avadel Pharmaceuticals plc Class of relevant security to which the dealings being disclosed relate (Note 2) $0.01 ordinary shares Date of dealing 09th February 2026 2.

Form 8.3 -Avadel Pharmaceuticals plc

Form 8.3 -Avadel Pharmaceuticals plc

FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORM A TION Name of person dealing (Note 1) State Street Global Advisors & Affiliates Company dealt in Avadel Pharmaceuticals plc Class of relevant security to which the dealings being disclosed relate (Note 2) $0.01 ordinary shares Date of dealing 06th February 2026 2.

Form 8.3 -Avadel Pharmaceuticals plc

Form 8.3 -Avadel Pharmaceuticals plc

FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORM A TION Name of person dealing (Note 1) State Street Global Advisors & Affiliates Company dealt in Avadel Pharmaceuticals plc Class of relevant security to which the dealings being disclosed relate (Note 2) $0.01 ordinary shares Date of dealing 05th February 2026 2.

Form 8.3 -Avadel Pharmaceuticals plc

Form 8.3 -Avadel Pharmaceuticals plc

FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORM A TION Name of person dealing (Note 1) State Street Global Advisors & Affiliates Company dealt in Avadel Pharmaceuticals plc Class of relevant security to which the dealings being disclosed relate (Note 2) $0.01 ordinary shares Date of dealing 04th February 2026 2.

Form 8.3 -Avadel Pharmaceuticals plc

Form 8.3 -Avadel Pharmaceuticals plc

FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORM A TION Name of person dealing (Note 1) State Street Global Advisors & Affiliates Company dealt in Avadel Pharmaceuticals plc Class of relevant security to which the dealings being disclosed relate (Note 2) $0.01 ordinary shares Date of dealing 03rd February 2026 2.

Form 8.3 -Avadel Pharmaceuticals plc

Form 8.3 -Avadel Pharmaceuticals plc

FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORM A TION Name of person dealing (Note 1) State Street Global Advisors & Affiliates Company dealt in Avadel Pharmaceuticals plc Class of relevant security to which the dealings being disclosed relate (Note 2) $0.01 ordinary shares Date of dealing 02nd February 2026 2.

Form 8.3 -Avadel Pharmaceuticals plc

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™